Tibet Rhodiola Pharmaceutical Holding Co Asset Resilience Ratio
Tibet Rhodiola Pharmaceutical Holding Co asset resilience ratio. Tibet Rhodiola Pharmaceutical Holding Co (600211) has an Asset Resilience Ratio of 11.84% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tibet Rhodiola Pharmaceutical Holding Co liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tibet Rhodiola Pharmaceutical Holding Co (2002–2025)
Asset resilience ratio of Tibet Rhodiola Pharmaceutical Holding Co from 2002 to 2025. This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's Asset Resilience Ratio has changed over time. Read Tibet Rhodiola Pharmaceutical Holding Co (600211) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Tibet Rhodiola Pharmaceutical Holding Co's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥762.18 Million | 11.84% |
| Total Liquid Assets | CN¥762.18 Million | 11.84% |
Asset Resilience Insights
- Moderate Liquidity: Tibet Rhodiola Pharmaceutical Holding Co has 11.84% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tibet Rhodiola Pharmaceutical Holding Co Industry Peers by Asset Resilience Ratio
Compare Tibet Rhodiola Pharmaceutical Holding Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Tibet Rhodiola Pharmaceutical Holding Co Asset Resilience Ratio by Year (2002–2025)
Tibet Rhodiola Pharmaceutical Holding Co asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Tibet Rhodiola Pharmaceutical Holding Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.45% | CN¥1.78 Billion ≈ $260.89 Million |
CN¥6.27 Billion ≈ $917.12 Million |
+7.87pp |
| 2024-12-31 | 20.57% | CN¥976.62 Million ≈ $142.91 Million |
CN¥4.75 Billion ≈ $694.68 Million |
+9.34pp |
| 2023-12-31 | 11.23% | CN¥515.34 Million ≈ $75.41 Million |
CN¥4.59 Billion ≈ $671.27 Million |
-8.10pp |
| 2022-12-31 | 19.33% | CN¥792.49 Million ≈ $115.97 Million |
CN¥4.10 Billion ≈ $599.87 Million |
+5.19pp |
| 2021-12-31 | 14.14% | CN¥537.87 Million ≈ $78.71 Million |
CN¥3.80 Billion ≈ $556.45 Million |
+13.64pp |
| 2020-12-31 | 0.51% | CN¥14.96 Million ≈ $2.19 Million |
CN¥2.94 Billion ≈ $430.84 Million |
-2.74pp |
| 2019-12-31 | 3.25% | CN¥90.00 Million ≈ $13.17 Million |
CN¥2.77 Billion ≈ $404.93 Million |
+0.41pp |
| 2016-12-31 | 2.84% | CN¥65.00 Million ≈ $9.51 Million |
CN¥2.29 Billion ≈ $335.20 Million |
+2.80pp |
| 2010-12-31 | 0.04% | CN¥308.80K ≈ $45.19K |
CN¥735.47 Million ≈ $107.62 Million |
-0.05pp |
| 2009-12-31 | 0.10% | CN¥709.60K ≈ $103.84K |
CN¥743.70 Million ≈ $108.83 Million |
+0.08pp |
| 2008-12-31 | 0.01% | CN¥112.40K ≈ $16.45K |
CN¥829.66 Million ≈ $121.41 Million |
-0.03pp |
| 2007-12-31 | 0.04% | CN¥339.80K ≈ $49.72K |
CN¥831.96 Million ≈ $121.74 Million |
+0.01pp |
| 2006-12-31 | 0.03% | CN¥252.00K ≈ $36.88K |
CN¥866.90 Million ≈ $126.86 Million |
+0.02pp |
| 2005-12-31 | 0.01% | CN¥114.60K ≈ $16.77K |
CN¥820.62 Million ≈ $120.08 Million |
-0.46pp |
| 2004-12-31 | 0.48% | CN¥3.69 Million ≈ $540.55K |
CN¥777.25 Million ≈ $113.74 Million |
-0.03pp |
| 2003-12-31 | 0.51% | CN¥3.81 Million ≈ $557.96K |
CN¥754.36 Million ≈ $110.39 Million |
+0.05pp |
| 2002-12-31 | 0.46% | CN¥3.37 Million ≈ $492.55K |
CN¥733.08 Million ≈ $107.27 Million |
-- |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more